Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% – Here’s What Happened

Posted by Brenda Bartman on Sep 28th, 2026

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) traded up 5.7% during trading on Monday. The company traded as high as $4.91 and last traded at $4.9360. Approximately 1,725,473 shares changed hands during mid-day trading, a decline of 41% from the average session volume of 2,924,317 shares. The stock had previously closed at $4.67.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TSHA. Bank of America raised their target price on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Citizens Jmp restated a “market outperform” rating and issued a $11.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, July 2nd. BMO Capital Markets lifted their target price on Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, June 23rd. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research report on Tuesday, June 23rd. Finally, The Goldman Sachs Group raised their price target on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $12.77.

Get Our Latest Analysis on TSHA

Taysha Gene Therapies Stock Performance

The business’s 50-day simple moving average is $5.70 and its two-hundred day simple moving average is $5.68. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -12.00 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the transaction, the insider directly owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors and hedge funds have recently modified their holdings of TSHA. R Squared Ltd acquired a new stake in Taysha Gene Therapies in the 1st quarter valued at about $50,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Taysha Gene Therapies in the first quarter valued at approximately $51,000. Principal Financial Group Inc. increased its holdings in shares of Taysha Gene Therapies by 26.2% in the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after purchasing an additional 3,362 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Taysha Gene Therapies by 698.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock worth $141,000 after buying an additional 22,373 shares in the last quarter. Finally, Cetera Investment Advisers boosted its stake in Taysha Gene Therapies by 34.5% during the first quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock worth $127,000 after buying an additional 7,296 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

(Get Free Report)

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company developing gene therapies for severe monogenic diseases of the central nervous system. The company focuses on disorders in which a missing or defective gene contributes to neurological disease and uses adeno-associated virus (AAV) vectors to deliver functional genetic material to targeted cells.

Taysha’s development programs have included TSHA-102, an investigational gene therapy for Rett syndrome, and earlier programs such as TSHA-120 for giant axonal neuropathy and TSHA-101 for GM1 gangliosidosis.